Where is Lucence located?

Lucence is headquartered in Singapore, Singapore. It is registered at HENDERSON ROAD, Singapore, 159552.

Which legal entities is Lucence associated with?

Lucence is associated with LUCENCE LIFE SCIENCES PTE. LTD. and 1 other.

How many employees does Lucence have?

As of Oct 31, 2026, the latest employee count at Lucence is 101.

Where does Lucence rank among its competitors?

Lucence ranks 121st amongst 400 active competitors, of which 133 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was 4baseCare, which secured an undisclosed amount in Jul, 2026.

Who are the top competitors of Lucence?

Lucence's top competitors include Geneoscopy, 4baseCare and Caris Life Sciences. Among them, 4baseCare secured the most recent funding round in July, 2026.

Lucence - 2026 Company Profile, Team, Funding, Competitors & Financials

Lucence is a funded company based in Singapore (Singapore), founded in 1999 by Min-Han Tan. It operates as a Developer of genomic tests for the treatment of cancer. The company has 400 active competitors, including 133 funded and 86 that have exited. Its top competitors include companies like Geneoscopy, 4baseCare and Caris Life Sciences.

Company Details

Lucence is a developer of genomic tests for the treatment of cancer. It has developed precision oncology genomic tests that is non-invasive blood tests that help in the detection and improve treatment selection. Genomic medicines help in the detection of cancer before symptoms show and check for genetic risk of developing cancer. It has developed a SAFER Sample that is a proprietary formula of virus transport medium that preserves viral ribonucleic acids at room temperature for up to a week without the need for chilling. It is a non-invasive specimen collection & helps in the transport of samples. The product is compatible with qPCR testing procedures.

Website: www.lucence.com/
Social
Email ID: *****@lucence.com
Phone Number: +65 **********
Registered Address: HENDERSON ROAD, Singapore, 159552

Key Metrics

Founded Year

1999

Location

Singapore, Singapore

Stage

Funding Raised

Investors

Openspace Capital & 1 more

Ranked

121^st among 400 active competitors

Employee Count

101 as on Oct 31, 2026

Similar Companies

Geneoscopy & 545 more

View Lucence's full profile

Lucence is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
LUCENCE LIFE SCIENCES PTE. LTD. UEN: 201816193K , Singapore, Active	May 11, 2018	-	-
LUCENCE DIAGNOSTICS PTE. LTD. UEN: 201605840N , Singapore, Active	Mar 07, 2016	-	-

Lucence is a funded company. Lucence has 2 institutional investors.

View details of Lucence's funding rounds and investors

The founders of Lucence is Min-Han Tan.

Here are the details of Lucence's key team members:

Min-Han Tan: Founder & CEO of Lucence and founder of 1 other company. They serve on the board of 1 company.

Lucence's Board of Directors

Lucence's board has 3 active members. Min-Han Tan and Tan Kim Lee are part of team and Lim Kaling is independent board member.

Here is the list of Lucence's board of directors:

Name	Type	Representing	Status	Duration
Min-Han Tan	Team	-	Current	10y 6m
kernpmh	Team	-	Current	9y 5m
Lim Kaling	Independent board member	-	Current	6y 10m
antyesy	Independent board member	-	Past	5y 5m
nfdzpms	Independent board member	-	Past	2y 6m

View details of Lucence's Founder profiles and Board Members

Lucence's employee count trend

Lucence has 101 employees as of Oct 26. Here is Lucence's employee count trend over the years:

Uncover Lucence's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lucence include Geneoscopy, 4baseCare and Caris Life Sciences. Here is the list of Top 10 competitors of Lucence, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
2nd	4baseCare 2018, Bengaluru (India), Series B	Provider of precision oncology solutions, including genomic testing and digital health	$25.9M	Tremis Consultancy, Yali Capital & 41 others	67/100
3rd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	66/100
4th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Novartis & 10 others	66/100
5th	NeoGenomics 2002, Fort Myers (United States), Public	Provider of cancer genetic diagnostic services	-	Ranger Investments, Aspen Capital & 1 others	63/100
6th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
7th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	62/100
8th	Personalis 2011, Menlo Park (United States), Acquired	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 5 others	61/100
9th	GenSight Biologics 2011, Paris (France), Public	Developer of viral vector-based gene therapies for retinal neurodegenerative diseases	$76.6M	Perceptive Advisors, Fidelity Investments ... & 17 others	61/100
10th	Repare Therapeutics 2016, Montreal (Canada), Acquired	Developer of targeted therapies to address the genetic alterations associated with selected tumors	$166M	Versant Ventures, Cowen & 13 others	60/100
121st	Lucence 1999, Singapore (Singapore), Funding Raised	Developer of genomic tests for the treatment of cancer	-	Openspace Capital, Centurion Investment Management	48/100